Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRAIN III: BCG Strains Comparison in Guinea-Bissau
NCT04383925Phase 4Completed
- Sponsor
- Bandim Health Project
- Start
- May 2020
- Primary completion
- Oct 2022
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of BCG Japan in Tuberculosis (TB) and Infection (2 arms), sponsored by Bandim Health Project. Primary endpoint: Rate of all-cause mortality at 6 weeks. Started May 2020; status: completed.
02
Drugs
BCG Japan
03
Conditions
Tuberculosis (TB)Infection
Beyond the preview
Go deeper on NCT04383925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383925.